OncoMed Pharmaceuticals Inc (OMED)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

800 CHESAPEAKE DRIVE REDWOOD CITY, CA 94063

OncoMed Pharmaceuticals Inc. provides biotechnology research and development. The Company synthesizes oncogenic mutations in stem cells that allows the cells to grow without normal limitations in attempts to exploit therapies that selectively target tumor initiating cells. OncoMed serves the healthcare industry and cancer therapy patients.

Data as of 2019-05-24 23:17:09 -0400
Market Cap34.434 Million Shares Outstanding38.69 Million Avg 30-day Volume
P/E Ratio Dividend Yield0.0 EPS-0.16
Price/Sales0.94154 Debt to Equity EBITDA0
Price to Book Value0.75 Forward PE Enterprise Value
Total Cash0 Current Debt Gross Profit0
BETA1.76515 52-week High/Low3.35 / 0.54672 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from OMED instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OMED (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OMED BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LEWICKI JOHN A. PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2019-04-23 0

ROOT JONATHAN D

  • Director
No longer subject to file 2019-04-23 0

LASERSOHN JACK W

  • Director
No longer subject to file 2019-04-23 0

PAKIANATHAN DEEPIKA

  • Director
No longer subject to file 2019-04-23 0

HAGER ALICIA J. SVP AND GENERAL COUNSEL

  • Officer
No longer subject to file 2019-04-23 0

KARSEN PERRY A

  • Director
No longer subject to file 2019-04-23 0

LI YVONNE SEE REMARKS

  • Officer
No longer subject to file 2019-04-23 0

STAGG ROBERT SEE REMARKS

  • Officer
No longer subject to file 2019-04-23 0

GURNEY AUSTIN SEE REMARKS

  • Officer
No longer subject to file 2018-12-24 0

POLLARD-KNIGHT DENISE

  • Director
0 2018-06-22 0

WYZGA MICHAEL S

  • Director
0 2018-06-22 0

WINNINGHAM RICK E

  • Director
0 2018-06-22 0

PATEL SUNIL SEE REMARKS

  • Officer
0 2018-01-04 0

HASTINGS PAUL J CHAIRMAN & CEO

  • Officer
401,028 2017-10-10 0

LASKY LAURENCE

  • Director
0 2017-06-01 0

HOEY TIMOTHY SVP, CANCER BIOLOGY & CO-CSO

  • Officer
77,225 2017-04-23 0

DUPONT JAKOB SVP & CHIEF MEDICAL OFFICER

  • Officer
34,440 2016-10-09 0

GOULD TERRY P

  • Director
0 2016-06-22 0

PRESIDIO MANAGEMENT GROUP VIII L L C

US VENTURE PARTNERS VIII L P

USVP VIII AFFILIATES FUND L P

USVP ENTREPRENEUR PARTNERS VIII A L P

USVP ENTREPRENEUR PARTNERS VIII B L P

FEDERMAN IRWIN

KRAUSZ STEVEN M

LIDDLE DAVID E

TANSEY CASEY M

YOUNG PHILIP M

  • 10% Owner
No longer subject to file 2014-08-08 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments